LOS ANGELES - s4story -- Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.

Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).

$15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.

2025 Shareholder Update Issued from CEO.

Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.

Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.

Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.

Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.

Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.

RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.

RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

$15 Million in New Equity Committed

On February 26^th RENB announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.

More on S For Story

• On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
• NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
• DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
• CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
• Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)

David Weinstein, Chief Executive Officer of Renovaro, commented, "We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."

Shareholder Letter and Corporate Update

On January 7^th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:

Dear Shareholders,

We have identified three areas as mission critical for building the point of care cancer detection, personalized therapy and vaccine business are: we need to acquire large amounts of data, build the business of clinical decision support for oncologists, and monetize our AI though building and licensing predictive models for drug repurposing and our cancer vaccine. We are meeting these three challenges through the acquisition of Predictive Oncology.

RENB recently signed a binding letter of intent to acquire Predictive Oncology (Stock Symbol: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.

When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines.  There are two business developments that RENB is pursuing.

Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.

GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.

More on S For Story

• High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
• Murder, Mystery, and Merriment in the Cotswolds: Buttons & Betrayal Brings Cozy Crime to Life
• Introducing Easy Living Vision Board Book: A Practical Guide to Designing Your Dream Life
• What Iran-Contra Still Reveals About U.S.–Israel–Iran Relations—And the Dallas Story Few Know
• Luminary Publishing House Marks Strong Start to Its Second Year with a Fourfold Increase

To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.

Maurice van Tilburg, RENB Chairman, has decided to join full time as the CEO of the  AL/ML subsidiary, GEDiCube. Renovaro management, including Mr. van Tilburg.

Further strengthening the management team, RENB has brought Nathen Fuentes on board as CFO. On the corporate front, NASDAQ notified that the company is now in good standing.

For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/

Media Contact
Company Name: Renovaro Inc. (Stock Symbol: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and  https://www.compasslivemedia.com/renb/
Email: ir@renovarobio.com
Phone:  732-780-5036
Home Country: United States

DISCLAIMER:  https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website